Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics DTIL

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Precision BioSciences Inc

DTIL
Current price
4.61 USD +0.01 USD (+0.22%)
Last closed 4.52 USD
ISIN US74019P2074
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 53 556 004 USD
Yield for 12 month -53.34 %
1Y
3Y
5Y
10Y
15Y
DTIL
21.11.2021 - 28.11.2021

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew St., Durham, NC, United States, 27701

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

30.50 USD

P/E Ratio

Dividend Yield

Financials DTIL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+68 696 000 USD

Last Year

+48 727 000 USD

Current Quarter

+29 000 USD

Last Quarter

+638 000 USD

Current Year

+68 696 000 USD

Last Year

+40 472 000 USD

Current Quarter

+29 000 USD

Last Quarter

+638 000 USD
EBITDA -41 431 000 USD
Operating Margin TTM -76 248.27 %
Price to Earnings
Return On Assets TTM -17.83 %
PEG Ratio
Return On Equity TTM -50.81 %
Wall Street Target Price 30.50 USD
Revenue TTM 51 141 000 USD
Book Value 4.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -99.80 %
Dividend Yield
Gross Profit TTM 51 141 000 USD
Earnings per share -2.87 USD
Diluted Eps TTM -2.87 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -42.99 %

Stock Valuation DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.11
Enterprise Value Revenue 0.097
Price Sales TTM 1.05
Enterprise Value EBITDA -0.27
Price Book MRQ 1.06

Technical Indicators DTIL

For 52 Weeks

3.61 USD 11.09 USD
50 Day MA 4.88 USD
Shares Short Prior Month 545 676
200 Day MA 5.87 USD
Short Ratio 7.13
Shares Short 1 298 128
Short Percent 5.08 %